Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical Industry Clamps Down On Counterfeit Drugs

This article was originally published in PharmAsia News

Executive Summary

A conference was held on Jan. 22 to 25 in Guangzhou, China, to rally the pharmaceutical industry to crackdown on counterfeit drugs. According to the China Association for Technical Supervision Information, the national consortium for anti-counterfeit pharmaceuticals worked with authorities in 2007 to investigate more than 120 fake products and 30 infringement rights cases. Counterfeit drugs accounted for 60 percent of the cases investigated, while two-thirds were infringement cases. Counterfeiters have been duplicating and selling branded drugs despite China's crackdown on counterfeiting. As the activity causes business losses and poses a serious threat to public health, experts exhort the industry to assume more responsibilities and actions to deter such incidents. (Click here for more - Chinese Language)

You may also be interested in...



Pipeline Acquisitions, Co-Promotion Deals, To Drive Ipsen

Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.

Biden COVID-19 Plan Would Grow Domestic Manufacturing Base

The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.

People On The Move: Appointments At Sanofi, Enzymatica And Bayer

Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.

UsernamePublicRestriction

Register

ID1132542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel